Term neuropharmacology describes studying the effect of an exogenous molecule on the nervous system. Common afflictions of the nervous system, such as Alzheimer's disease, Parkinson's Disease, Multiple sclerosis, Autism, Epilepsy, Depression, Schizophrenia, and HIV-associated Neurocognitive disorders, are awaiting effective medications, further emphasizing the importance of neuropharmacology.
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. Unfortunately, to date, there is no cure for neurodegenerative/neurological/neuropsychiatric diseases, and they continue to represent one of the most prominent therapeutic challenges. This suggests that current therapeutic approaches are palliative and do not address the absolute symptoms of the diseases that could be due to complex phenotype and substantial clinical heterogeneity. Therefore, to reduce the incidence and halt or slow the progression of these disorders, an understanding of drug molecular and cellular actions with their effects on brain circuitry is fundamental. Researchers are taking advantage of techniques such as single-cell Omics, gene-targeted silencing, RNA and mitochondrial sequencing, machine learning as well as combinatorial chemistry to generate novel molecules that may function as new promising drugs. We hope that in-vitro and in-vivo studies using leads from clinical-epidemiological studies will provide new insights into the molecular mechanism of the above-mentioned disorders and help to identify novel therapeutic targets and develop new drugs.
In this Special Issue of Frontiers in Pharmacology on "Neuropharmacology of Neuro –degenerative, -logical, -psychiatric disorders" we welcome reviews, mini-reviews, new methods, and original research articles that advance our understanding of the molecular mechanism of these disorders to develop a better therapeutic strategy and a lead molecule that can be developed as an effective drug.
Term neuropharmacology describes studying the effect of an exogenous molecule on the nervous system. Common afflictions of the nervous system, such as Alzheimer's disease, Parkinson's Disease, Multiple sclerosis, Autism, Epilepsy, Depression, Schizophrenia, and HIV-associated Neurocognitive disorders, are awaiting effective medications, further emphasizing the importance of neuropharmacology.
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. Unfortunately, to date, there is no cure for neurodegenerative/neurological/neuropsychiatric diseases, and they continue to represent one of the most prominent therapeutic challenges. This suggests that current therapeutic approaches are palliative and do not address the absolute symptoms of the diseases that could be due to complex phenotype and substantial clinical heterogeneity. Therefore, to reduce the incidence and halt or slow the progression of these disorders, an understanding of drug molecular and cellular actions with their effects on brain circuitry is fundamental. Researchers are taking advantage of techniques such as single-cell Omics, gene-targeted silencing, RNA and mitochondrial sequencing, machine learning as well as combinatorial chemistry to generate novel molecules that may function as new promising drugs. We hope that in-vitro and in-vivo studies using leads from clinical-epidemiological studies will provide new insights into the molecular mechanism of the above-mentioned disorders and help to identify novel therapeutic targets and develop new drugs.
In this Special Issue of Frontiers in Pharmacology on "Neuropharmacology of Neuro –degenerative, -logical, -psychiatric disorders" we welcome reviews, mini-reviews, new methods, and original research articles that advance our understanding of the molecular mechanism of these disorders to develop a better therapeutic strategy and a lead molecule that can be developed as an effective drug.
